Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a human growth hormone presented as a recombinant protein for subcutaneous use. It is used to treat growth hormone deficiency and related growth disorders in children and adults.

GNH USA supplies Norditropin Flexpro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Norditropin Flexpro provides recombinant human growth hormone therapy for several endocrine and genetic growth disorders. - Growth hormone deficiency: restores normal growth velocity and improves body composition. - Turner syndrome: promotes linear growth and helps achieve near‑normal adult height. - Chronic renal insufficiency: supports growth in children with renal disease. - Prader‑Willi syndrome: improves growth parameters and body composition. - Short stature associated with Noonan syndrome: enhances height outcomes during childhood.

Norditropin Flexpro may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema - Headache - Transient edema of the extremities - Joint stiffness or arthralgia - Nausea or abdominal discomfort - Hyperglycemia or impaired glucose tolerance

Serious or Rare Side Effects: - Intracranial hypertension - Development of anti‑growth hormone antibodies - Slipped capital femoral epiphysis - Acute pancreatitis - Severe allergic reactions (anaphylaxis) - Increased intracranial pressure leading to visual disturbances

Before initiating therapy, clinicians should evaluate relevant medical history and monitor patients regularly. - Assess baseline IGF‑1 levels: adjust dose based on serial measurements. - Monitor glucose metabolism: watch for hyperglycemia, especially in diabetic patients. - Screen for intracranial hypertension: be alert to headaches and visual changes. - Evaluate for scoliosis progression: regular orthopedic assessments are recommended. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin may interact with other agents that affect glucose homeostasis or hormone pathways.

Major Interactions (Avoid): - High‑dose glucocorticoids: may blunt growth‑promoting effects. - Insulin or oral hypoglycemics: increased risk of hypoglycemia when combined with somatropin‑induced insulin resistance.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: somatropin can increase thyroxine requirements. - Estrogen therapy: may enhance IGF‑1 response, requiring dose adjustment. - Anabolic steroids: additive effects on growth may increase risk of adverse musculoskeletal events.